Defence Therapeutics Inc Class A · CSE:DTC
Defence Therapeutics Inc Class A — Investor Presentation (November 2025)
30 slides from Defence Therapeutics Inc Class A's investor presentation, November 2025
Slide 1: Investor Presentation
Investor Presentation Biopharmaceutical Innovations for Future Generations CSE: DTC | FSE: DTC | OTCQB: DTCFF Q4 2025
Slide 2: Our Journey
Investor Presentation | Defence Therapeutics Our Journey Accum Technology Licensed from Established R&D laboratory at Sherbrooke University Montreal Innovation Park AccuTox approved for First-in-human trials + Defence from FDA and HC Key Hires Therapeutics Launched 2020 2021 2022 2023 2024 2025 2026
Slide 3: Leadership
Investor Presentation | Defence Therapeutics Leadership Dr. Amie Phinney Sébastien Plouffe Dr. Sarkis Meterissian Strategy & Business, Director CEO, Founder & Director Medical Lead, Director PhD, MBA with 20 years experience in Financial expert and entrepreneur with 30+ years World renowned oncologi
Slide 4: Scientific Team
Investor Presentation | Defence Therapeutics Scientific Team Dr. Maxime Parisotto Dr. Philippe Lefrançois Clinical Advisory, Director Chief Scientific Officer, Director Business Director of Research in the dermatology Development division at McGill University. Dermatologist PhD, MBA. Lead Scientist wit
Slide 5: Our Technology
Investor Presentation | Defence Therapeutics Our Technology Cholic acid moiety that facilitates efficient endosomal escape Peptide sequence that drives targeted delivery to the Peptide cell nucleus Direct injection into solid tumors stimulates Cholic acid microenvironment to immune activate tumors At
Slide 6: Our Value-inflection Year
Investor Presentation | Defence Therapeutics Our Value-inflection Year Defence Therapeutics 2026 Strategic Plan Accum® platform programs are well-positioned to achieve value-inflection within 12 months 6
Slide 7: 2026: Our value-inflection year
Investor Presentation | Defence Therapeutics 2026: Our value-inflection year China Bio AACR Int’l Bio JP Morgan Conference Conference Conference World ADC ARC ARC World ADC Conference Publication Dev Conference London Candidate USA ADC ARC Biotech/ Biotech/ ACCUM P1b DMF First Patient Pharma Pharma S
Slide 8: Our Value-inflection programs
THE HIGHLIGHTS Defence Therapeutics Our Value-inflection programs 8
Slide 9: The AccuTOX Program
9 CANCER THERAPEUTICS The AccuTOX ® Program: Ready for Phase I in Canada, FDA clearance: Study May Proceed in the USA Indication: Melanoma 9
Slide 10: AccuTOX
Investor Presentation | Defence Therapeutics AccuTOX® Dimers of Accum® have a therapeutic activity by themselves without being conjugated to any biologics + Accum® Accum® AccuTOX® 10 Bikorimana JP, et al., J Transl Med. 2024 Jun 3;22(1):532.
Slide 11: AccuTOX-001 Halts Tumor Development With Immune-Checkpoint Inhibitors
Investor Presentation | Defence Therapeutics AccuTOX®-001 Halts Tumor Development When Combined with Immune-Checkpoint Inhibitors (ICI) Synergistic effect against Tumor Microenvironment Enhancer ICI-resistant Tumors that activates T-cells 11 Bikorimana JP, et al., J Transl Med. 2024 Jun 3;22(1):532.
Slide 12: AccuTOX Clinical Trial
Investor Presentation | Defence Therapeutics AccuTOX® Clinical Trial • Approved for trail start in both USA/FDA and Canada/HC • Two sites are activated in Canada • Recruitment starting in Q1 2026 12
Slide 13: The Accum +ADC Program
13 CANCER THERAPEUTICS The Accum +ADC Program:® Expanding patient access and market opportunities for ADCs 13
Slide 14: Problem for Antibody-delivered Drugs
Investor Presentation | Defence Therapeutics Problem for Antibody-delivered Drugs Antibody conjugated ! drugs efficiently ‘target’ cells, but are inefficient Endosome intracellular navigators that often fail to hit the Cargo (biologics) ‘bullseye’ Dose 100x Entrapment ADCs must be delivered ! Endocyto
Slide 15: Our Solution: Accum
Investor Presentation | Defence Therapeutics ® Our Solution: Accum Defence Therapeutics’ Innovative Drug Delivery Platform Accum® Molecule Endosome Nucleus Escape tag Beacon ! Adding Accum® to an Antibody-conjugated drug will: Engineered molecular ‘tag’ that can be added to a any biologic drug •Redu
Slide 16: The Solution: Accum
Investor Presentation | Defence Therapeutics The Solution: Accum® Defence Therapeutics’ Innovative Drug Delivery Platform ! Accum®-labelled biologics escape endosomes Endosome entrapment and degradation - enhancing their intracellular Cargo (biologics) “Accum®ulation” Dose 10x. Entrapment ! Endocyto
Slide 17: Confirmed In Vivo PoC for ADC+Accum
Confirmed In Vivo PoC for Investor Presentation | Defence Therapeutics ADC+Accum® Experiment demonstrating head to head superiority vs ADC alone ADC ADC ADC 0.5mg/kg ADC @ 0.5mg/kg Non-effective dose ACCUM-ADC 0.5mg/kg Effective dose 17 ! RESULT : Accum® makes an ineffective dose effective
Slide 18: Accum has transformational potential for antibody delivered drugs
Accum® has transformational Investor Presentation | Defence Therapeutics potential for antibody delivered drugs Current advised doses for ADCs= 3.6mg/kg Plasma Free [Toxin] = ~7 nM ~40–50% of ADC-treated patients What if Extrapolated dose of ACCUM- ADCs= 0.72mg/kg Plasma Free [Toxin] =~1.4 nM ~0 % o
Slide 19: The Power of Accum
The Power of Accum® Investor Presentation | Defence Therapeutics ! On-market ADCs are approved as second-line therapies only due to the dose-limiting ! Potent ADCs could be suitable first-line therapies, expanding patient access toxicities and market opportunities Kadcyla Enhertu Trastuzumab $2.2B $3
Slide 20: Advancing ADC's beyond today's limits
Investor Presentation | Defence Therapeutics Advancing ADC’s beyond today’s limits Novel IP for endosome escape Works across all ADCs tested Greater drug availability Striking results in vivo models 20 confidential
Slide 21: Accum-enhanced Radionuclide Drug Conjugates (RDC)
21 CANCER THERAPEUTICS Accum ®-enhanced Radionuclide Drug Conjugates (RDC) Programs: Indications: Solid Tumors 21
Slide 22: Radiopharmaceuticals Programs
Investor Presentation | Defence Therapeutics Radiopharmaceuticals Programs 1) Accum®/AccuTOX® - Actinium 225 • 100% owned by Defence • Collaboration with the Canadian Nuclear Laboratories to perform the studies • Development of targeted radiopharmaceuticals therapy using Accum® & AccuTOX® with Actin
Slide 23: Connect
Connect (514) 947 - 2272 info@defencetherapeutics.com www.defencetherapeutics.com Laboratories and Offices: 7171 Frederick Banting Montreal, QC, H4S 1Z9
Slide 24: The Highlights
THE HIGHLIGHTS Defence Therapeutics ● Publicly traded biotech firm based in Montreal, Canada, with an attractive capital structure and long-term investors. ● Worldwide extensive patent portfolio covering the Accum® platform technology; 8 granted US patents to date. ● FDA clearance and NOL from Health
Slide 25: AccuTOX/Hydrogels
Investor Presentation | Defence Therapeutics AccuTOX®/Hydrogels STEROID ACID-PEPTIDE BASED CYTOTOXIC COMPOUNDS Filing date: Nov. 16, 2022 ; 20-year patent term expiry: Nov. 16, 2042 Jurisdiction Application no. Status Patent no. Biologic(s) covered United States US 18/056,110 Granted US 11,890,350 U
Slide 26: Accum-ADCs/RICs
Investor Presentation | Defence Therapeutics Accum®-ADCs/RICs CONJUGATES ENHANCING TOTAL CELLULAR ACCUMULATION Filing date: Mar. 15, 2017 ; 20-year patent term expiry: Mar. 15, 2037 Jurisdiction Application no. Status Patent no. Biologic(s) covered United States US 16/085,141 Granted US 11,352,437 J
Slide 27: Vaccines/intracellular delivery
Investor Presentation | Defence Therapeutics Vaccines/intracellular delivery COVALENTLY MODIFIED ANTIGENS FOR IMPROVED IMMUNE RESPONSE AND/OR STABILITY Filing date: Nov. 1, 2021 ; 20-year patent term expiry: Nov. 1, 2041 Jurisdiction Application no. Status Patent no. Biologic(s) covered United State
Slide 28: Bibliography Articles
Investor Presentation | Defence Therapeutics Bibliography Articles 1. Lacasse V et al., Mol Ther Methods Clin Dev. 2020 Sep 1;19:99-119. 2. Paquette M et al., Bioconjug Chem. 2018 Apr 18;29(4):1352-1363. 3. Beaudoin S et al., Mol Pharm. 2016 Jun 6;13(6):1915-26. 4. El-Kadiry AE et al., Molecules. 20
Slide 29: DEFN-101: Accum Enhanced On-Market ADC
Investor Presentation | Defence Therapeutics DEFN-101: Accum Enhanced On-Market ADC ADC vs Cell line 1 ADC vs Cell line 2 % Cell survival % Cell survival ADC ADC +Accum® +Accum® Concentration Concentration ! Data confirms, Accum® dramatically enhances potency of multiple ADCs and multiple cancer cell
Slide 30: Validation of Accum with a novel ADC
Investor Presentation | Defence Therapeutics Validation of Accum® with a novel ADC Tumor Volume (mm3) % Cell survival ADC-X (1 mg/kg) + Accum (1 mg/kg) Days ! RESULT : Accum may revive ADCs abandoned in development, unlocking new markets 30
Defence Therapeutics — Investor Presentation (November 2025) on 6ix